BCL2 and plasma cell myeloma: In human xenograft models of small-cell lung cancer, multiple myeloma, lymphoblastic leukaemia, and aggressive B-cell lymphoma, Bcl-2/Bcl-XL inhibitors were previously shown to significantly enhance the efficacy of clinically relevant therapeutic regimens [21], [23]–[25].